Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Recruiting 13Completed 12Unknown 7Active not recruiting 7Terminated 4Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Sarcoma 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Colorectal Neoplasms 49Rectal Neoplasms 32Pancreatic Neoplasms 28Colonic Neoplasms 24Stomach Neoplasms 19Neoplasm Metastasis 15Neoplasms 13Esophageal Neoplasms 10Breast Neoplasms 7Head and Neck Neoplasms 6Recurrence 5Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Adenocarcinoma Of Esophagus 5Lymphoma, Large B-Cell, Diffuse 4Carcinoma, Hepatocellular 4Ovarian Neoplasms 3Lymphoma, Extranodal NK-T-Cell 3Liver Neoplasms 3Gastrointestinal Neoplasms 3Gallbladder Neoplasms 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3Adenocarcinoma 3Unspecified Adult Solid Tumor, Protocol Specific 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Peritoneal Neoplasms 2Myelodysplastic Syndromes 2Melanoma 2Lymphoma, Non-Hodgkin 2

Interventions

Rituximab 67Cyclophosphamide 41fludarabine phosphate 17Etoposide 17Doxorubicin 17Vincristine 16Prednisone 16Filgrastim 14Mycophenolic Acid 13Cyclosporine 13Lenalidomide 12Antilymphocyte Serum 12Gemcitabine 11Radiotherapy 10fludarabine 9Peripheral Blood Stem Cell Transplantation 9Methotrexate 9Whole-Body Irradiation 8Tacrolimus 8Melphalan 8Carboplatin 8Bortezomib 8venetoclax 7Dexamethasone 7Cord Blood Stem Cell Transplantation 7Busulfan 7ibritumomab tiuxetan 6Ifosfamide 6Flow Cytometry 6obinutuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Large B-Cell, Diffuse × Oxaliplatin × Clear all
NCT03422523 2022-08-22

ARGO

University Hospital Southampton NHS Foundation Trust

Phase 2 Terminated
53 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03488251 2022-08-16

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

Molecular Templates, Inc.

Phase 2 Terminated
8 enrolled 9 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02951156 2020-12-17

Javelin DLBCL

Pfizer

Phase 3 Terminated
29 enrolled 24 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT00101205 2014-02-24

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
40 enrolled
DermatologicLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Mycosis Fungoides, Recurrence, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡